Followers | 77 |
Posts | 18699 |
Boards Moderated | 3 |
Alias Born | 04/16/2019 |
Monday, October 03, 2022 1:06:48 PM
Truly amazing.
Recent SHPH News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/30/2024 04:15:07 AM
- Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 10/30/2024 01:05:52 AM
- Shuttle Pharma Pays Off Senior Secured Convertible Note • GlobeNewswire Inc. • 10/29/2024 08:05:00 PM
- Micro Cap Company Is Soaring On Phase 2 Trial Update • AllPennyStocks.com • 10/29/2024 04:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/29/2024 01:00:26 PM
- Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma • GlobeNewswire Inc. • 10/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2024 08:05:10 PM
- Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma • GlobeNewswire Inc. • 10/28/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2024 01:00:39 PM
- Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024 • GlobeNewswire Inc. • 10/28/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 12:52:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2024 09:17:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 09:00:06 PM
- Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma • GlobeNewswire Inc. • 09/16/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 09:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 09:23:05 PM
- Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease • GlobeNewswire Inc. • 09/05/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/04/2024 08:26:42 PM
- Shuttle Pharma Provides Second Quarter 2024 Corporate Update • GlobeNewswire Inc. • 09/04/2024 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/04/2024 01:54:28 AM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 09/04/2024 01:52:57 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 09/04/2024 01:51:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 01:00:44 PM
- Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/28/2024 01:00:00 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM